We are international
Donate
TEXT SIZE   


ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports LENALIDOMIDE Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
04.04.07
The Eastern Cooperative Oncology Group (ECOG) has reported that its Data Monitoring Committee's (DMC) review of preliminary results from a large, randomized clinical trial for patients with newly diagnosed multiple myeloma has found that the use of a low dose of dexamethasone (Decadron) in combination with lenalidomide suggests survival advantage for patients when compared to the higher, standard-dose of dexamethasone that is used in combination with lenalidomide to treat the disease.


 related articles
THE INTERNATIONAL MYELOMA FOUNDATION SAYS ECOG RESULTS COULD IMPROVE SURVIVAL WHILE REDUCING SIDE EFFECTS FOR MANY PATIENTS
Mayo Clinic Press Release: Multiple Myeloma Clinical Trial Closes Early Due to Superior Results of Comparative Treatment
National Cancer Institute Press Release: Low-dose Steroid Combined with Lenalidomide Prolongs Survival Compared with High-dose Steroid for Multiple Myeloma Treatment
National Institutes of Health Press Release: Low-dose Steroid Combined with Lenalidomide Prolongs Survival Compared with High-dose Steroid for Multiple Myeloma Treatment
Understanding Revlimid®
Understanding Thalidomide Therapy
Understanding Dexamethasone and Other Steroids


You might also be interested in:

THE INTERNATIONAL MYELOMA FOUNDATION SAYS ECOG RESULTS COULD IMPROVE SURVIVAL WHILE REDUCING SIDE EFFECTS FOR MANY PATIENTS
Findings Challenge Traditional Assumption that More-Is-Better when Treating Cancer

Mayo Clinic Press Release: Multiple Myeloma Clinical Trial Closes Early Due to Superior Results of Comparative Treatment
Mayo Clinic Cancer Center announced today that a multiple myeloma clinical trial has shown a significant improvement in survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone.

National Cancer Institute Press Release: Low-dose Steroid Combined with Lenalidomide Prolongs Survival Compared with High-dose Steroid for Multiple Myeloma Treatment

National Institutes of Health Press Release: Low-dose Steroid Combined with Lenalidomide Prolongs Survival Compared with High-dose Steroid for Multiple Myeloma Treatment
The clinical trial was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG).

Understanding Revlimid®
Learn more about Revlimid® (lenalidomide), approved by the FDA for use in myeloma.

Understanding Thalidomide Therapy
Using thalidomide to treat myeloma is a new idea, but thalidomide itself has been studied for many decades.

Understanding Dexamethasone and Other Steroids
What dexamethasone is, how it works, possible side effects, and more.